穿刺活检标本中的前列腺外延伸是高风险但可局部治疗前列腺癌的典型表现
该单中心回顾性研究纳入2005至2016年Princess Margaret癌症中心127例诊断性前列腺穿刺活检报告前列腺外延伸(EPE)的非转移性前列腺癌患者,均接受根治性前列腺切除(RP)或放疗(RT)±雄激素剥夺治疗(ADT)。RP组95.3%为≥pT3a期、27.9%为pN1;RP与RT组5年生化复发率分别为25.6%与11.9%(p=0.09),转移率分别为7%与11.9%(p=0.386)。作者认为穿刺活检EPE不应妨碍患者接受根治性局部治疗。
要点
- 穿刺活检报告EPE与高风险临床病理特征强相关,可准确预测RP标本中的EPE。
- RP与RT组5年生化复发率25.6%对11.9%(p=0.09),转移率7%对11.9%(p=0.386)。
- 尽管伴侵袭性疾病特征,穿刺活检EPE不应妨碍患者接受根治性局部治疗。
核心结论
- 穿刺活检EPE是不常见发现,与高风险临床病理预后特征强相关,并能准确预测RP标本中的EPE。
- 尽管伴侵袭性疾病特征,穿刺活检EPE不应妨碍患者接受根治性局部治疗。
研究设计与样本
- 单中心回顾性研究,纳入Princess Margaret癌症中心2005至2016年诊断性前列腺穿刺活检报告EPE的非转移性前列腺癌患者127例。
- 所有患者接受根治性前列腺切除(RP,n=43,占三分之一)或放疗(RT,n=84,占三分之二)±雄激素剥夺治疗(ADT)。
主要发现
- 两组基线预后变量(前列腺特异性抗原、临床T分期、活检病理分级分组、穿刺针受累比例)相似。
- RT组超过三分之二接受同期ADT(中位时长36个月,四分位距24-36),RP组39.5%接受术后放疗±ADT。
- RP组95.3%为≥pT3a期,27.9%为pN1。
- RP与RT组中位随访时间相似(43.7对45.8个月;p=0.516)。
- RP与RT组5年生化复发率分别为25.6%与11.9%(p=0.09),转移率分别为7%与11.9%(p=0.386);仅1例患者死于转移性前列腺癌(RT组)。
临床怎么用
- 作者认为,穿刺活检发现EPE不应妨碍患者接受根治性局部治疗。
局限性
- 单中心回顾性设计。
- 样本量中等。
- 随访时间相对较短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Extraprostatic extension (EPE) is defined as local spread of prostate cancer (PC) beyond prostate boundaries. Although extensively evaluated in radical prostatectomy (RP) specimens, its significance in prostate biopsy (PB) specimens is understudied. OBJECTIVE: To analyze the clinicopathologic characteristics and treatment outcomes for patients with nonmetastatic PC with EPE on diagnostic PB. DESIGN, SETTING, AND PARTICIPANTS: We identified all patients at Princess Margaret Cancer Center with EPE on their diagnostic PB between 2005 and 2016. All patients underwent definitive curative-intent treatment with either RP or radiotherapy (RT) with or without androgen deprivation therapy (ADT). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSES: Clinicopathologic variables were compared using a χ2 or Kruskal-Wallis test; log-rank analyses were applied for outcomes comparison. Primary and secondary endpoints were 5-yr biochemical recurrence (BCR) and the occurrence of metastasis or cancer-specific death, respectively. RESULTS AND LIMITATIONS: A total of 127 patients with reported EPE in their PB were identified. One-third of patients underwent RP (n=43) and two-thirds received RT (n=84). Baseline prognostic variables (prostate-specific antigen, clinical T stage, biopsy pathologic grade group, and proportion of cores involved with PC) were similar between the treatment groups. More than two-thirds of RT patients received concomitant ADT (median duration 36 mo, interquartile range 24-36), while 39.5% of RP patients received postoperative radiotherapy±ADT. Of the RP patients, 95.3% had ≥pT3a disease and 27.9% had pN1 disease. Median follow-up after RP and RT was similar (43.7 vs 45.8 mo; p=0.516). The 5-yr BCR and metastasis rates in the RP versus RT groups were 25.6% versus 11.9% (p=0.09) and 7% versus 11.9% (p=0.386), respectively. Only one patient died from metastatic PC (RT group). Limitations include the single-center and retrospective design with a moderate sample size and relatively short follow-up. CONCLUSIONS: EPE on PB is an infrequent finding that is strongly associated with high-risk clinicopathologic prognostic features that accurately predict EPE in RP specimens. Despite entailing aggressive disease characteristics, EPE on PB should not preclude patients from receiving definitive radical local therapy. PATIENT SUMMARY: Extraprostatic extension on prostate biopsies is an uncommon finding, but is strongly correlated to additional aggressive disease features. This finding accurately predicts the presence of extraprostatic extension on the final prostate specimen after surgery. Despite the associated high-risk features, finding extraprostatic extension in prostate biopsies should not preclude patients from undergoing curative-intent radical local therapy.
引用
- Goldberg H, Ramiz AH, Glicksman R, et al. Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer. Eur Urol Oncol. 2018. PMID: 30929849. doi:10.1016/j.euo.2018.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。